Generic Prices Are Falling But Patient Costs Rise

Generic medicine prices have been falling for three years but some patients are experiencing higher out-of-pocket costs. That doesn’t add up. When patients are burdened with higher Rx costs than ever, it makes no sense that there are forces keeping safe, effective and affordable generic and biosimilar medicines from getting approved, and being accessible to patients.

GENERICS NOT AVAILABLE

Generics Not Available Or Covered

Fewer than half of the first generics (the first to compete with brand-name drugs) approved by FDA since 2016 are commercially available to patients. Of those that are commercially available, only half are included on formularies of Medicare Part D plans.That doesn’t add up.

SENIORS PAYING BILLIONS MORE

Seniors Paying Billions More Than Necessary

Since 2015, seniors have paid nearly $22 billion in needless out-of-pocket costs for their prescription drugs in Medicare Part D because health plans are placing them on higher formulary tiers. That doesn’t add up. If plans automatically put generic drugs on generic tiers with lower out-of-pocket costs, seniors will see immediate benefits.

BIOSIMILAR PROMISE NOT REALIZED

Biosimilar Promise Not Realized

Biologic medicines are the costliest and fastest growing category of drug spending. Biosimilars hold great promise to be more affordable alternatives to expensive biologics, but only 9 of 23 biosimilars that have been approved by FDA are available to U.S. patients. That doesn’t add up.

TAKE ACTION

Sick of paying outrageous prices for your prescription medicines?

Send a message to your lawmakers to tell them, “This Doesn’t Add Up.” Real stories from real patients make a real difference.

SEND A MESSAGE NOW

Resources

Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage Delays

Since 2006, the Medicare Part D program has successfully provided seniors access to lifesaving medicines while stewarding taxpayer resources. Today, the program serves more than 45 million seniors.

READ THE WHITE PAPER

Resources

White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access and savings by providing competition for costly brand-name biologics.

READ THE WHITE PAPER

Resources

2019 Generic Drug and Biosimilars Access and Savings in the U.S.

The 11th annual edition of AAM’s Savings and Access Report quantifies how much money American patients and our health care system are saving because of generic and biosimilar alternatives to brand-name prescription and biologic medications.

READ THE SAVINGS REPORT

Resources


Generic costs have been going down but many patients are paying more for these medicines. That doesn’t add up.

Let’s be transparent. The makers of generic medicines want you to know how much our drugs cost so we can have an informed discussion of drug prices.

Generic Cost Vs. Brand Cost.

TV Spots

Seniors Paying Billions More Than They Should — #DoesntAddUp

First Generics Not Available Or Covered — #DoesntAddUp